Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Rachel Howard
  • December 18, 2019
  • Articles

How were the teenies? Reflecting on global healthcare and market research over the last decade

How were the teenies? Reflecting on global healthcare and market research over the last decade

Back in 2010, I presented my perspective on what the 2010s might look like for healthcare market research and business intelligence at the BHBIA Winter Seminar. As we round out the decade, I thought it would be timely to revisit my predictions and consider which of them actually came to fruition over the last decade, which did not, and why. My first reaction, looking back over my (already horrifyingly dated looking) PowerPoint slides, was to cringe at the nickname I’d assigned to the coming years – “the teenies”. Much like “the noughties” before them, that never caught on. Fortunately, from that point on, the rest of my predictions proved a little more prescient – “on the right track, but a little wide of the mark” is how one of my colleagues summarised them. 

read more »

  • Posted by Pei Li Teh
  • February 21, 2019
  • Articles

International Women's Day: Addressing women's health in emerging markets

International Women's Day: Addressing women's health in emerging markets

Friday 8th March 2019 marks International Women's Day, a global day of action aimed at accelerating gender equality and improving women's health. Asia-Pacific Director Pei Li Teh reflects on why this is such an important issue in emerging markets.

International Women’s Day is a commemoration of the social, economic, and cultural achievements of women around the world. Furthermore, the day marks a global call to action for accelerating gender parity by improving women’s access to education and quality, affordable healthcare. Since its inception in 1909, International Women’s Day has made tremendous progress to advance gender equality. Nevertheless, figures show that globally, women’s health indicators still lag behind those of men in many aspects. 

read more »

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.

read more »

  • Posted by Rachel Howard
  • July 6, 2017
  • Blogs, News

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global health landscape through bilateral programs, health partnerships, and the support of multilateral organisations, as well as influencing global health policy and international health research.  Its future has come under increasing scrutiny following the UK referendum result in favour of leaving the EU last year, and again in the wake of last month’s general election result.  

read more »

  • Posted by Rachel Howard
  • February 15, 2017
  • Articles

Cool heads in a crisis?

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years.  Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone. 

read more »